Health
Study supports continuing phase 3 trials of Ad26.COV2.S SARS-CoV-2 vaccine – News-Medical.Net
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being…
An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being tested in phase 3 trials for its ability to protect against infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).
The vaccine comprises a recombinant adenovirus serotype 26 (Ad26) vaccine vector expressing a stabilized form of the SARS-CoV-2 spike antigen that the…
-
Noosa News16 hours agoHow Lily Steele-Park took her rapist to court and won
-
Business21 hours agoFord CEO makes stunning prediction about artificial intelligence
-
Business19 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025
-
General22 hours agoRush to buy homes before rate cuts send prices soaring